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Zachariah A. McIver,1 Jan J. Melenhorst,1 Andrew Grim,1 Nicholas Naguib,1 Gerrit Weber,1
Vicki Fellowes,2 Hahn Khuu,2 David S. Stroncek,2 Susan F. Leitman,2
Minoo Battiwalla,1 A. John Barrett1We evaluated an ex vivo photodepletion (PD) technique to selectively deplete graft-versus-host disease
(GVHD) alloreacting T cells given to 24 human leukocyte antigen (HLA)-identical sibling stem cell transplan-
tation (SCT) recipients. Donor lymphocytes were activated by 72-hour exposure to irradiated in vitro
expanded recipient T lymphocytes and pulsed with a TH9402 photosensitizer. Alloactivated T cells prefer-
entially retaining the photosensitizer were eliminated by light exposure. The PD product showed an inverted
CD41/CD81 ratio with greatest depletion occurring in the CD41 naive and central memory populations. In
contrast, the CD81 naive and effector cells were relatively conserved, reflecting the differential extrusion of
TH9402 by T cell subsets. Cytomegalovirus reactive T cells were reduced in the PD product and in recipient
blood 100 days after SCT when compared with contemporaneous HLA-identical sibling donor T cell-
depleted SCTrecipients. Although PD SCTrecipients experienced similar absolute lymphocyte counts during
the first 100 days after SCT, they achieved 100% donor T cell chimerism more rapidly and had higher CD81
naive T cell counts early after SCT. SCTrecipients of PD products with the lowest CD4 central memory con-
tent had the highest risk of developing chronic GVHD (cGVHD) (P 5 .04) and a poorer survival (P 5 .03).
Although the persistence of CD81 naive T cells may have contributed to important antileukemia responses
resulting in a relatively low relapse rate, our findings emphasize the role of donor memory T cells and CD4
cells in establishing immune competence post-SCT. Although PD is associated with excellent outcomes in the
haploidentical setting, the low frequency of alloactivations in HLA-matched pairs makes the PD approach
used by our group for allodepletion in HLA-matched sibling transplantations an inefficient technique.
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6/j.bbmt.2011.05.017morbidity and mortality associated with severe graft-
versus-host disease (GVHD) and delayed immune
reconstitution. The GVHD alloresponse can be pre-
vented or reduced in severity by posttransplantation
immune suppression and T cell depletion (TCD), but
with a risk of impairing antiviral and antitumor re-
sponses of the incoming donor immune system [1].
One approach to selectively reduce the risk of GVHD
is to stimulate the donor lymphocyte product before
transplantation with recipient antigen-presenting cells
(APC), and then subsequently target and eliminate
host-alloreactive T cells [2-5]. We recently conducted
a clinical trial using a photodepletion (PD) technique
to selectively deplete host-reacting T cells from
HLA-matched sibling SCTs with the goal of reducing
acute GVHD (aGVHD). This PD technique was de-
signed to target p-glycoprotein differences between ac-
tivated and nonactivated cells, and had been validated
in major histocompatibility complex-mismatched
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After stimulation with recipient APCs, alloactivated
donor T cells were eliminated based on their
preferential retention of the photosensitizer 4,5-
dibromorhodamine 123 (TH9402) and exposure to vis-
ible light (Kiadis Pharma, The Netherlands). Preclini-
cal studies demonstrated that photodepleted cell
products retained third-party alloreactivity and cyto-
megalovirus (CMV) reactivity, while losing allo-
reactivity to the original stimulator. The PD
approach was equally applicable to HLA-matched
and mismatched donor-recipient pairs [8]. After FDA
and institutional review board approval, 24 patients
were enrolled in the clinical trial. However, because
of recurrent infections and increased rates of chronic
GVHD (cGVHD), we elected to close the trial early.
The clinical results of this study are reported separately
[9]. Here we describe the characteristics of the PD
product and associated abnormalities of immune re-
constitution and transplant outcome in this patient
group. The data are contrasted with a contemporane-
ous group of patients receiving an identical preparative
regimen and aTCDSCTwith 5 104 CD31 cells /kg.PATIENTS, MATERIALS, AND METHODS
Patients
Between July 2006 and October 2010, 24 patients
underwent a PD SCT and 35 patients underwent
a TCD SCT from an HLA-identical sibling on the
National Heart, Lung and Blood Institute institutional
review board -approved protocols (07-H-0136 and 06-
H-0248). Patients and donors provided written in-
formed consent before enrolling in the transplantation
protocol.Reagents for Flow Cytometry
The following monoclonal antibodies (mAb) and
fluorescent dyes were used: from Beckman Coulter
(Fullerton, CA): a-CD27-Cy5-phyocoerythrin (Cy5PE;
clone 1A4CD27); from Becton Dickinson (BD;
Fullerton, CA): a-CD3-AmCyan (clone SK7), a-CD4-
V500 (clone PRA-T4), a-CD4-Cy7PE (clone SK3),
a-CD8-H7-allophycocyanin (H7APC), or -Cy7APC
(clone SK1), a-CD107a-fluorescein isothyocyanate
(FITC; clone H4A3), a-CD25-FITC (clone 2A3),
a-Macrophage inflammatory protein-1b (MIP-1b)-PE
(cloneD21-1351), a-tumor necrosis factor-a (TNF-a) -
Cy7PE (clone Mab 11), a-CD154-APC (clone
TRAP1), a-FOXP3-APC (clone 229D/C7), a-CD28
(clone L293), and a-CD49d (clone L25); from
Invitrogen (Carlsbad, CA): a-CD3 Quantum Dot
605 (QD605; clone UCHT1), a-CD14-pacific blue
(PB; clone TuK4), a-CD19-PB (clone SJ25-C1),
a-CD45RO-PE (clone UCHL1), the violet deadcell-exclusion dye ViViD, and the cell tracker dye
5-(and-6)-carboxyfluorescein diacetate, succinimidyl
ester (CFSE).
Generation of Recipient Stimulator Cells
Details of the technique used to produce the
PD product were previously reported [8]. Briefly,
ex vivo-expanded T lymphocytes from the recipient
were used as stimulator cells because of the ease of ob-
taining sufficient numbers of stimulators potentially
free of myeloid and B cell-derived antigens that might
later induce a graft-versus-leukemia effect. These
stimulator cells were generated from immunomagneti-
cally CD3-selected T cells (Miltenyi Biotech, Bergisch
Gladbach, Germany) obtained from a single leukaphe-
resis product (8- to 12-liter blood volume processed).
After selection, CD31 cells were cultured in X-
VIVO 20 (Cambrex Bio Science, Walkersville, MD)
supplemented with 2% autologous heat-inactivated
plasma and 100 IU/mL interleukin-2 (Proleukin; Chi-
ron, Emeryville, CA) in gas-permeable polyolefin tis-
sue culture bags (Lifecell PL732; Baxter Cellular
Therapies, Deerfield, IL) precoated with OKT3 anti-
body (murumonab-CD3, Orthoclone OKT3; Ortho
Biotech, Horsham, PA). Cells were then incubated at
37C, 7% CO2, and 90% humidity with fresh medium
added to maintain the cell concentration between
0.5  106 and 1.5  106 cells/mL. Stimulator cells
were harvested after 10 to 12 days, and then concen-
trated, washed, and cryopreserved.
Coculture
Cells were thawed, gamma irradiated (25 Gy), re-
suspended in X-VIVO 20 (Cambrex Bio Science) sup-
plemented with 2% autologous heat-inactivated
plasma, at a concentration of 5  106 cells/mL, and
then combined with responder cells at a ratio of 1:1.
Responder and irradiated stimulator cells were cocul-
tured for 72 hours at 37C, 7% CO2. Cocultures
were performed in gas-permeable polyolefin tissue
culture bags. Following the 72-hour coculture, cells
were concentrated in preparation for PD.
Photodepletion
Following the coculture, concentrated cells were
resuspended at a concentration of 5  106 cells/mL
and incubated at 37C with 7.5 mM of 4,5-
dibromorhodamine 123 (TH9402; Kiadis Pharma,
The Netherlands). After 40 min of incubation, cells
were centrifuged and resuspended in TH9402-free
medium (X-VIVO 20 without phenol red, Cambrex
Bio Science) supplemented with 2.5% plasma for
90 min to allow dye efflux. After the 90-min dye extru-
sion period, cells were exposed to visible light using
a fluorescent light-scanning device (Theralux device,
Model 514; Kiadis) delivering 5 J/cm2 at a wavelength
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were cryopreserved at a final concentration of 5% di-
methyl sulfoxide and 6% pentastarch, and then trans-
ferred into a liquid nitrogen tank at liquid or vapor
phase (2200C to 2150C) for storage until thaw
and distribution.
Transplantation Procedure
Patients on both the PD and TCD protocols re-
ceived a conditioning regimen of fludarabine (125
mg/m2 over 5 days), fractionated total body irradiation
(TBI) (12Gy; 4.0Gy if over 55 years) in 8 fractions over
4 days, followed by cyclophosphamide (120mg/kg over
2 days). Depletion of T cells from the SCT products
was accomplished by positive selection of CD341 cells
using the Miltenyi CliniMacs system (Miltenyi Biotec
Inc., Auburn, CA). On the day of SCT, all patients re-
ceived this enriched CD341 stem cell product with
a target dose of 5  106 CD341 cells/kg. Patients
undergoing a TCD (06-H-0248) SCT received a pre-
determined dose of 5  104T cells/kg with the stem
cell product that was adjusted by adding back T cells
from the selection process if necessary. Patients
enrolled in the PD protocol (07-H-0136) received
5  106 photodepleted CD31 cells/kg.
Enumeration of T Cell Subsets
Samples of the lymphocyte allograft before and after
PD, and peripheral blood mononuclear cell (PBMC)
samples were collected at 100 days after SCT and cryo-
preserved. In preparation for analysis, PBMC were
thawed and rested overnight. Cell staining was done es-
sentially as previously described [10,11]. Data were
acquired on a CantoII flow cytometer (BD) and
analyzed using FACSDiva (BD, version 6.1) or FlowJo
(Version 8.6.6., Treestar, Ashland, OH). T cell subsets
were defined as follows: Naive CD271CD45RO2,
Central Memory CD271CD45RO1, Effector Memory
CD272CD45RO1, and Effectors CD272CD45RO2.
Regulatory T cells (Tregs) are defined as CD41
CD251FOXP31 T cells.
Measurement of P-Glycoprotein Activity
To evaluate P-Glycoprotein (Pgp) activity, elutri-
ated lymphocytes from 8 volunteer donors were stained
with ViViD and mAb to CD3, CD4, CD8, CD14,
CD19, CD45RO, and CD27 as previously reported
[12], washed, and then resuspended at a concentration
of 5  106 cells/mL in X-VIVO 10 (Cambrex Bio Sci-
ence) containing 7.5 mM TH9402 for 40 minutes at
37C. Cells were than centrifuged and resuspended
X-Vivo 10 free of TH9402 in the presence of absence
or verapamil (10 mM, Sigma, St. Louis, MO). Flow cy-
tometry was then performed on a CantoII flow cytom-
eter. In accordance with standardmethods, Pgp activity
was determined by the difference in TH9402 medianfluorescence intensity in the presence and absence of
verapamil [13]. Data were analyzed using FACSDiva
software.
Proliferation Assays
Measurement of in vitro proliferation was per-
formed by themethod ofCFSEdilution [14]. Immuno-
magnetically selected T cells were used as responder
cells, and the CD3-depleted fraction from the same
donor was used for antigen presentation (APC). Iso-
lated CD31 cells were stained with 0.5 mM of CFSE
(Invitrogen) and incubated at 37C for 7 minutes.
CFSE was quenched by adding 1 mL of normal AB se-
rum (NABS, Gemini Bio-Products, West Sacramento,
CA) for 2 minutes, and the cells were washed twice in
RPMI 1640 containing 10% NABS. Stimulator cells
were labeled with 0.5 nM of Far Red (Invitrogen) fol-
lowing the same procedure. Fully HLA-disparate
healthy donor cells were used as targets for the mea-
surement of third-party reactivity, and all targets
were irradiated with 25 Gy. Responder cells (5  104)
were stimulated in 96 round-bottom plates with an
equal number of with autologous APC loaded with 1
mg/mL custom-synthesized peptide library, covering
the entire open reading frames of either CMV immedi-
ate early-1 (IE1) or phosphoprotein 65 (pp65) [15],
both from Princeton Biomolecules, Inc. (Langhorne,
PA), in the presence of 1 mg/mL a-CD28 and a-
CD49d for costimulation. Staphylococcus entero-
toxin B (SEB, Toxin Technology, Inc., Sarasota, FL)
was used as a positive control. After 6 days, cells were
harvested and stained with ViViD, followed by stain-
ing with mAb to CD3, CD4, CD8, CD14, and CD19
as outlined above, and acquired on a LSRFortessa
(BD). List mode files were analyzed using FlowJo.
T Cell Functional Assays
To determine the reactivity of T cells with viral
antigens, PBMCs were thawed and rested as outlined
above, and then stimulated with pretitered amounts of
the IE1 and pp65 peptide library, or cell lysates pre-
pared from an adenovirus (Ad)-, CMV-, influenza-,
or varicella zoster virus-infected cell line. As a control,
a lysate from an uninfected cell line was used. All ly-
sates were from Microbix. Stimulations were per-
formed in 96-well U-bottom plates, and in the
presence of the cytokine secretion blockers brefeldin
A (Golgiplug; BD), monensin (Golgistop; BD),
a-CD107a-FITC, a-CD28, and a-CD49d. After 6
hours at 37C/5% CO2, the cells were washed and
stained with ViViD and mAb to cell surface antigens
as described above, followed by intracellular staining
for MIP-1b, TNF-a, and CD154 using Cytofix/cyto-
perm and Cytoperm/cytowash kit (BD). The cells
were acquired on a LSRFortessa, and data were exam-
ined using FlowJo.
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Limited cGVHD was defined as localized skin in-
volvement resembling scleroderma with or without
liver involvement; no other organ involvement pres-
ent. Extensive cGVHD was defined as generalized
skin or multiple organ involvement [16]. Overall sur-
vival (OS) was defined as the number of days after
SCT of death.
Statistical Analysis
Survival was measured to the last contact date or
death. Univariate analysis was performed using
log-rank and Cox proportional-hazard regression
models. Multivariate analyses were performed using
Cox proportional-hazard regression model and in-
cluded all factors associated with a P value \.2 by
univariate analysis. A stepwise backward procedure
was then used with a cutoff significance level of .05
to remove factors from the model. P values are 2
sided, with a type I error rate fixed at .05. Statistical
analyses were performed with SPSS version 15.0
(SPSS, Inc., Chicago, IL) and Prism 4 (GraphPad
Software, San Diego, CA) software.RESULTS
Cellular Characteristics of Photodepleted
Products
Details of the photodepleted products given are
listed in Table 1. All PD cell products were preparedTable 1. Characteristics of PD Products
Patient
SCT CD34/kg
(106)
SCT CD3/kg
(102)
PD CD3/kg
(106)
Viabili
Proces
1 6.0 6.2 5.0 9
2 7.9 8.1 5.0 8
3 6.0 25.7 5.0 9
4 5.4 11.3 5.0 8
5 9.5 0 5.0 9
6 6.0 0 5.0 8
7 4.9 5.2 5.0 8
8 7.3 24.8 5.0 9
9 6.7 20.3 5.0 9
10 7.3 70.0 5.0 9
11 4.4 9.1 5.0 8
12 3.9 19.4 5.0 7
13 3.1 10.9 5.0 9
14 9.6 29.0 5.0 7
15 6.3 0 5.0 9
16 6.9 59.6 5.0 9
17 7.9 16.2 5.0 9
18 4.7 9.6 5.0 8
19 3.6 16.3 5.0 8
20 7.3 7.5 5.0 7
21 6.8 27.7 5.0 8
22 7.6 7.7 5.0 9
23 6.9 21.2 5.0 9
24 5.0 10.0 5.0 9
Median 6.5 11.1 5.0 9
PD indicates photodepletion; SCT, stem cell transplantation.within 5 hours of the PD process and were adjusted
to a final dose of 5 10e6CD3+ cells/ kgwith amedian
viability (6 SEM) of 90% 6 1.4% at time of prepara-
tion. However, after thawing and resting, the median
viability of products fell to 66% 6 2.3%. The relative
frequency of the T cell subsets also changed following
PD. The CD41 T cell compartment experienced
a greater degree of depletion causing an inversion of
the CD41/CD81 ratio. Within the CD41 compart-
ment, Tregs were relatively enriched (Figure 1C),
but there was a significant depletion of naive, central
memory, and effector populations with a relative
preponderance of the effector memory subset. Con-
versely, within the CD81T cell compartment, the fre-
quency of na€ıve and effector subsets was conserved
with depletion predominantly in the central memory
population. Additionally, an 80% reduction in B cells
occurred. Cytotoxic (CD561CD161) NK cells were
reduced by 60%, whereas regulatory (CD561CD162)
NK cells were well preserved (Figure 1).Dye Efflux Variability Across T cell Subsets
Efflux of TH9402 was determined following
a 90-minute extrusion period that was performed after
a 40-minute coloration period. Overall, CD81 T cells
displayed a stronger efflux of TH9402 than CD41
T cells, indicating increased Pgp activity. Among the
T cell subsets, TH9402 extrusion varied dramatically
(Figure 2). Naive CD81 T cells eliminated dye most
efficiently with a median (6SEM) of 38% 6 7%
actively extruding dye after 90 minutes. Centralty After
sing (%)
Viability After
Thaw (%)
CD4/CD8 Ratio
Before PD
CD4/CD8
Ratio After PD
3 48 1.63 0.56
7 81 0.94 0.77
3 58 No Sample 0.93
9 73 0.78 0.74
6 53 0.89 0.57
7 59 1.68 1.15
6 61 1.40 0.29
2 71 3.13 2.11
0 76 2.06 No Sample
2 82 3.11 2.23
7 67 1.57 2.32
3 51 2.77 No Sample
3 48 3.60 1.51
0 75 1.13 1.37
2 52 1.78 2.05
1 73 1.01 0.68
3 77 3.97 0.79
7 65 0.91 0.56
4 65 2.21 2.57
5 47 1.02 0.94
5 50 2.06 0.79
5 83 2.03 0.76
0 73 2.47 0.73
6 75 1.35 1.16
0 66 1.67 0.56
  CD3    CD4    EM   CM   Naive   Effector
0
20
40
60
80
100
T cell Subset
t
n
e
c
r
e
P
  CD3    CD8    EM   CM   Naive   Effector
0
20
40
60
80
100
T cell Subset
t
n
e
c
r
e
P
0
20
40
60
80
100
Total NK cells CD56+CD16+ CD56+CD16- B cells
t
n
e
c
r
e
P
Before PD After PD
0
1
2
3
s
g
e
r
T
t
n
e
c
r
e
P
Figure 1. Changes in frequency of T cell subsets after PD. Mean percentage6 SEM of the (A) CD4, (B) the CD8 T cell subsets, (C) Tregs, and (D) NK
and B cells before (solid bar) and after PD (white bar).
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sion (20 6 8%), whereas effector memory, central
memory, and naive CD41 T cell subsets showed the
most dye retention; a median of only 13 6 3% of the
total CD41 cells were actively extruding TH9402 at
the end of the 90-minute period (Table 2). After 4.5
hours inTH9402-freemedium, the difference in extru-
sion among the subsets was more apparent with 28 6
5% of the CD41 and 66% 6 15% of CD81 popula-
tions actively extruding dye. Although the Pgp activity
in naiveCD41Tcells increased to levels comparable to
the other CD41 subsets with a longer extrusion time,
the naive CD81 T cell subset maintained the greatest
extrusion capacity (76% 1 9%). The variability in
dye extrusion between subsets was consistent with the
skewed proportions of CD41 and CD81 T cells
observed in the photodepleted products transfused.
CMV Reactivity in Photodepleted Products
CD41 and CD81 T cell reactivity with the immu-
nodominant CMV antigens IE1 and pp65 was assessedFigure 2. Differences in TH9402 extrusion of T cell suin cellular products from 12CMV1 donors before and
following PD using a proliferation-based assay. CMV
immunoreactivity was clearly detectable before PD.
However, all donor products demonstrated a loss of
anti-CMV activity in T cells after PD that was not re-
stored with the addition of the non-PD APC fraction.
Proliferative activity to SEB and third-party lympho-
cytes was retained (Figure 3).
Immune Reconstitution Posttransplantation of
PD Samples
The peripheral blood lymphocyte counts were
compared with a group of 24 patients receiving the
same conditioning regimen but given a transplant de-
pleted of T cells (final dose 5  104 CD31/kg). Lym-
phocyte recovery over the first 100 days is shown in
Figure 4. For patients who received a PD product, ab-
solute lymphocyte counts rose to a median of
761/mL 6 120 and 680/mL 6 264 by days 30 and
100, respectively, after SCT. Similarly, for patients
who received a TCD SCT, absolute lymphocytebsets in representative sample by flow cytometry.
Table 2. TH9402 Extrusion of T cell Subsets
Subset
TH9402 Extrusion
After 90 Minutes
Median ± SEM
TH9402 Extrusion
After 4.5 Hours
Median ± SEM
CD4 13% ± 3 28% ± 3
Naive 8% ± 3 34% ± 7
Central memory 14% ± 4 32% ± 12
Effector memory 14 % ± 4 28% ± 7
Effector 20% ± 4 23% ± 3
CD8 23% ± 7 66% ± 15
Naive 38% ± 7 76% ± 9
Central memory 20% ± 8 47% ± 10
Effector memory 28% ± 8 44% ± 9
Effector 31% ± 7 51% ± 16
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740/mL 6 131 by day 100. T cell phenotyping and
functional analysis was performed on day 100 periph-
eral blood samples in 16 patients of CMV1 donors
from the PD protocol and compared with results of
16 patients of CMV1 donors who received a TCD
SCT. Although the frequency and absolute concentra-
tions of T cells, B cells, and NK cells subsets were sim-
ilar in both protocols, patients receiving a PD product
had a higher frequency of naive CD81 T cells on day
100 after SCT (P 5 .025, Supplemental Material
Tables). Of all antigens tested, a decreased T cell re-
sponse to in vitro viral antigen stimulation was noted
in patients receiving a photodepleted product. Specif-
ically, no anti-CMV or anti-influenza reactivity was
detected in CD41 T cells, and a lack of anti-CMV
and anti-Ad reactivity was observed in the CD81 T
cell compartment (Figure 5). Clinically, this resulted
in a higher incidence of CMV reactivation that re-
quired treatment within the first 100 days after PD
SCT than observed after TCD SCT (median 2 vs 1
episode, P \ .05). The loss of anti-Ad andFigure 3. T cell proliferation against CMVantigens before and after PD.anti-influenza reactivity noted in samples of PD SCT
recipients collected 90 days after SCT could not be
evaluated for clinical impact because of the low inci-
dence of these viral infections occurring after SCT (4
adenoviral infections in TCDpatients; 3 adenoviral in-
fections in PD patients; and 1 influenza infection in
PD patient).T Cell Subset Allograft Content and Clinical
Outcomes
Variability of CD41 subset conservation within
PD products existed. Patients receiving a PD product
with low central memory CD41 T cell content had
lower absolute counts of CD41 central memory cells
on day 100 after SCT, increased rates of extensive
cGVHD, and lower OS by univariate analysis (log-
rank hazard ratio [HR] 7.7, P 5 .006) (Figure 6). On
multivariate analysis comparing the influence of recip-
ient age, donor sex match (female into male recipient
vs other combinations), disease status (high vs standard
risk hematologic malignancy), occurrence of aGVHD,
and the use of a donor lymphocyte infusion, only a low
CD41 CM frequency in the PD product was associ-
ated with cGVHD (HR5 0.931, P5 .038) and a worse
OS (HR5 0.92, P5 .028) (Figure 6). However, no as-
sociation was seen between any of the other T cell sub-
set frequencies in the PD allograft and the incidence of
transplant-related mortality or relapse. The clinical
outcomes of the PD SCT recipients are detailed sepa-
rately [9].DISCUSSION
The possibility of preventing GVHD by selec-
tively removing alloreactive T cells from the SCT
product has for more than a decade stimulated us
and numerous other investigators to develop selective
allodepletion strategies [2,4,17]. Our most recent
attempt using PD in the HLA-identical sibling trans-
plant setting resulted in encouragingly low rates of
aGVHD and relapse, but was complicated by a high
incidence of viral reactivation and high transplant-
related mortality, prompting early closure of the study
[9]. Here we report the characteristics of the trans-
planted T cell products and the subsequent immune
recovery in the recipient. We found the PD process
developed for HLA-identical sibling SCT resulted in
a skewed lymphocyte product with a relative depletion
of CD41 T cells, especially naive and central memory
CD41 T cells. In contrast, CD81 T cells were rela-
tively well preserved with an enrichment of the naive
subset. On further investigation, we found that the
changes in T cell subset frequencies following PD
were explained by subset differences in TH9402 reten-
tion. Dye retention was clearly greater in CD41 and
central memory cells, leading to their preferential
Figure 4. (A) Absolute lymphocyte counts during the first 100 days for patient receiving either a T cell depleted (open circles) or photodepleted (dark
squares) SCT. (B) T cell chimerism during the first 100 days after SCT.
1852 Biol Blood Marrow Transplant 17:1846-1854, 2011Z. A. McIver et al.elimination by PD (Table 2). These results are consis-
tent with earlier studies indicating that CD41 and cen-
tral memory T cells consistently have lower Pgp
activity [18].
These observations raise questions about the im-
pact of our PD process on immune recovery and trans-
plant outcome. One factor that could have affected
immune recovery was the viability of the PD product
because of the continuing in vitro attrition of dye-
treated cells. Although the CD31 T cell dose of the
PD product was adjusted for viability, the possibility
exists that a reduced number transplanted cells per-
sisted in the recipient. However, some viable cells
did persist after transplantation, which promoted
a more rapid conversion to full donor T cell chime-
rism in PD SCT recipients when compared with
TCD recipients who received 2 logs fewer T cells at
transplantation, suggesting that lymphocyte recovery
was not compromised by reduced viability of the pho-
todepleted product. Additionally, the nonselective
preferential depletion of some critical T cell subsets
that occurred during the PD process could have con-
tributed to a defective capacity of PD recipients to
handle infection, in particular, CMV reactivation,
and may have affected the tendency to develop
cGVHD. Indeed, proliferative responses to CMV
were significantly reduced in the PD product, and re-
activity to CMV remained much lower than in TCD
transplant recipients 100 days post-SCT. Intuitively,CD4 Response to CMV Lysate
PD TCD
-1
0
1
2
3
4
p = 0.0004
%
C
D
40
L+
T
N
F+
Figure 5. Ex vivo anti-CMV immune response in samples collected 100it might be assumed that the addition of 2 logs more
T cells at transplantation would provide greater im-
munity in the early post-SCT period than that con-
tained within a TCD graft. However, we found that
the CMV reactivation observed clinically within the
first 100 days after PD SCT was twice as frequent as
that observed after TCD SCT, indicating that the im-
mune repertoire rather than cell dose was a critical fac-
tor in determining viral immune competence. In
a multivariate analysis comparing the influence of re-
cipient age, donor sex match (female into male recip-
ient vs other combinations), disease status (high- vs
standard-risk hematologic malignancy), occurrence
of aGVHD, and the use of a donor lymphocyte infu-
sion, a low CD41 central memory frequency in the
PD product was associated with cGVHD and a worse
OS. In fact, of all the subsets studied, only CD41 cen-
tral memory frequency predicted clinical outcomes.
The importance of the various T cell subsets in im-
mune reconstitution has recently become more clearly
defined. CD81 central memory cells are critical to the
transfer of intact viral immunity, and CD41 central
memory cells are required for sustained antiviral mem-
ory [12,19], both of which were preferentially depleted
by PD. Also, CD41 T cell reconstitution may be
essential for development of immune tolerance and
the consequent control of cGVHD [20]. In accordance
with this observation, the preferential loss of CD41
T cells in PD may have contributed to cGVHDPD TCD-0.5
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(-log-rank HR 7.7, P 5 .006).
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Stem Cell Transplantationsdevelopment. In fact, because CD41 loss varied be-
tween products, we were able to evaluate the CD41
dose with incidence of cGVHD and found patients
who received a higher dose of CD41 central memory
in the PD allograft had significantly lower rates of ex-
tensive cGVHD. This relationship was also observed
when comparing CD41 central memory frequencies
in the donors ofTCDtransplantation (data not shown).
The probability of relapse for the PD and theTCD
groups was comparable (27% vs 35%, P 5 .61), sug-
gesting that graft-versus-leukemia was maintained in
the PD process. Although PD depletion as performed
in our study appears to have preferentially depleted
the CD41 cells that may be important for the develop-
ment of immune tolerance after SCT, the persistence
of naive CD81T cells may have contributed to impor-
tant antileukemia responses that resulted in a relatively
low relapse rate for this high-risk patient group. How-
ever, the study was not designed to evaluate the impact
of PD on disease relapse, and leukemic samples from
patients were not available to perform in vitro func-
tional analysis, prohibiting a definitive conclusion.
Finally, the impact of PD on Tregs deserves consid-
eration. Because effector Tregs mainly express a CD41
central memory phenotype, the frequency of central
memory CD41 T cells may represent a surrogate for
Treg content of the graft and potential levels after
SCT [20,21]. In our analysis, we found that the
frequency of Tregs within the CD41 compartment was
relatively enriched. However, the median frequency of
Tregs within the total T cell compartment was only
minimally increased compared with the enrichment of
CD81 T cells (median increase of 0.5% vs 9.6% of all
CD31 cells; P \ .01). Although no association was
seen between Treg frequencies and SCT outcomes, the
relative decrease of all CD41 T cell subsets would
suggest that the photodepleted products may be more
prone to cause GVHD.Our data contrast with the robust immune recon-
stitution reported for patients receiving haploidentical
SCT depletion of alloreacting cells by the same PD
technique reported by Roy et al. [22]. A possible expla-
nation for the difference in the immune recovery and
clinical outcome between our study and that of the
Montreal group is the differences in the strength of
the in vitro alloresponse between HLA-identical sib-
ling and haploidentical donor-recipient pairs. Allor-
eactivity in HLA-identical pairs is hard to elicit and
detect in vitro and insufficient to generate amixed lym-
phocyte reaction because of the very low frequencies of
alloreacting cells. Furthermore, we have shown that
stochastic factors determine which alloreacting T cell
clones are elicited in HLA-matched pairs. It is there-
fore possible that the low frequency and variable al-
loactivations in HLA-matched pairs are confounded
with background nonspecific activation, making PD
an inefficient technique for allodepletion in this setting
[23]. In contrast, haploidentical alloreactions induce
strong in vitro proliferation and T cell activation,
which likely facilitates selective depletion of alloacti-
vated cells with this technique. Another difference in
the PD technique used by our group that differs
from the Montreal study is the use of expanded T cells
rather than monocyte-containing APC. These non-
conventional APC may be less effective stimulators
or have a different spectrum of activation of T cell sub-
sets. These differences merit further investigation if
PD is to be used in the HLA-identical sibling setting.
In conclusion, we have shown that not only T cell
dose but T cell subset distribution can affect major
outcomes after SCT.The PDprocess produced a naive
CD81 enriched lymphocyte product that was rela-
tively deficient in CD41 T cells. As a result, patients
who received a PD SCT experienced a deficiency in vi-
ral immunity. Although the persistence of naive CD81
T cells may have contributed to important antileuke-
mia responses that resulted in a relatively low relapse
rate for this high-risk patient group, the nonspecific
depletion that occurred warrants caution. Although
PD is a promising allodepletion technique for haploi-
dentical SCT, further preclinical development to elim-
inate unwanted lymphocyte subset depletion is
indicated before applying PD to HLA-matched pairs.ACKNOWLEDGMENTS
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